Relevant shaking stress conditions for antibody preformulation development

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 74, Issue 2, 2010, Pages 139-147

  Eppler, Annette ^a,b   Weigandt, Markus ^a   Hanefeld, Andrea ^a   Bunjes, Heike ^b  

^a Merck Serono GmbH   (Germany)

^b TECHNICAL UNIVERSITY OF BRAUNSCHWEIG   (Germany)

Author keywords

Antibody formulation; Mechanical stress; Physical stability; Preformulation; Protein aggregation; Protein formulation; Shaking stress; Size exclusion chromatography; Stress conditions; Turbidity

Indexed keywords

BUFFER; IMMUNOGLOBULIN G ANTIBODY; MONOCLONAL ANTIBODY;

ANTIBODY PRODUCTION; ARTICLE; CONTAINER; CONTROLLED STUDY; DRUG STABILITY; GEL PERMEATION CHROMATOGRAPHY; MECHANICAL STRESS; PARTICLE SIZE; PREFORMULATION; PROTEIN AGGREGATION; SHAKING STRESS; TURBIDITY; ULTRAVIOLET SPECTROPHOTOMETRY;

ANTIBODIES, MONOCLONAL; CHEMISTRY, PHARMACEUTICAL; DRUG STABILITY; DRUG STORAGE; IMMUNOGLOBULIN G; NEPHELOMETRY AND TURBIDIMETRY; PROTEIN ENGINEERING; STRESS, MECHANICAL; TECHNOLOGY, PHARMACEUTICAL;

EID: 75449115351     PISSN: 09396411     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejpb.2009.11.005     Document Type: Article

References (27)

1. Pavlou A.K., and Belsey M.J. The therapeutic antibodies market to 2008. Eur. J. Pharm. Biopharm. 59 (2005) 389-396
2. Harris M. Monoclonal antibodies as therapeutic agents for cancer. Lancet Oncol. 5 (2004) 292-302
3. Wang W. Instability, stabilization, and formulation of liquid protein pharmaceuticals. Int. J. Pharm. 185 (1999) 129-188
4. Li S., Schoeneich C., and Borchardt R.T. Chemical instability of protein pharmaceuticals: mechanism of oxidation and strategies for stabilization. Biotechnol. Bioeng. 48 (1995) 490-500
5. Reubsaet J.L., Beijnen J.H., Bult A., van Maanen R.J., Marchal J.A.D., and Underberg W.J.M. Analytical techniques used to study the degradation of proteins and peptides: physical instability. J. Pharm. Biomed. Anal. 17 (1998) 979-984
6. Reubsaet J.L., Beijnen J.H., Bult A., van Maanen R.J., Marchal J.A., and Underberg W.J. Analytical techniques used to study the degradation of proteins and peptides: chemical instability. J. Pharm. Biomed. Anal. 17 (1998) 955-978
7. Chi E.Y., Krishnan S., Randolph T.W., and Carpenter J.F. Physical stability of proteins in aqueous solution: mechanism and driving forces in nonnative protein aggregation. Pharm. Res. 20 (2003) 1325-1336
8. Cleland J.L., Powell M.F., and Shire S.J. The development of stable protein formulations: a close look at protein aggregation, deamidation, and oxidation. Crit. Rev. Ther. Drug Carrier Syst. 10 (1993) 307-377
9. Mahler H.C., Muller R., Friess W., Delille A., and Matheus S. Induction and analysis of aggregates in a liquid IgG1-antibody formulation. Eur. J. Pharm. Biopharm. 59 (2005) 407-417
10. Kiese S., Papppenberger A., Friess W., and Mahler H.C. Shaken, not stirred: mechanical stress testing of an IgG1 antibody. J. Pharm. Sci. 10 (2008) 4347-4366
11. Ramsden W. Separation of solids in the surface-layers of solutions and suspension (observations on surface-membranes, bubbles, emulsions and mechanical coagulation. Proc. Roy. Soc. London 72 (1904) 156-164
12. Hazen K.C., Bourgeois L.D., and Carpenter J.F. Cryoprotection of antibody by organic solutes and organic solute/divalent cation mixtures. Arch Biochem. Biophys. 267 (1988) 363-371
13. Schellekens H. Factors influencing the immunogenicity of therapeutic proteins. Nephrol. Dial. Transplant. 20 Suppl. 6 (2005) 3-9
14. Carpenter J.F., Kendrick B.S., Chang B.S., Manning M.C., and Randolph T.W. Inhibition of stress-induced aggregation of protein therapeutics. Methods Enzymol. 309 (1999) 236-255
15. Sluzky V., Tamada J.A., Klibanov A.M., and Langer R. Kinetics of insulin aggregation in aqueous solutions upon agitation in the presence of hydrophobic surfaces. Proc. Natl. Acad. Sci. USA 88 (1991) 9377-9381
16. Wang W. Protein aggregation and its inhibition in biopharmaceutics. Int. J. Pharm. 289 (2005) 1-30
17. Patro S.Y. Protein formulation and fill-finish operations. Biotechnol. Ann. Rev. 8 (2002) 55-84
18. -F Maa Y., and Hsu C.C. Effect of high shear on proteins. Biotechnol. Bioeng. 51 (1996) 458-465
19. Philo J.S. Is any measurement method optimal for all aggregate sizes and types?. AAPS J. 8 (2006) E564-E571
20. Q1A(R2): Stability Testing of New Drug Substances and Products. International Conference on Harmonisation, 2003, pp. 1-15.
21. Eckhardt B.M., Oeswein J.Q., Yeung D.A., Milby T.D., and Bewley T.A. A turbidimetric method to determine visual appearance of protein solutions. J. Pharm. Sci. Technol. 48 (1994) 64-70
22. Maa Y.-F., and Hsu C.C. Protein denaturation by combined effect of shear and air-liquid interface. Biotechnol. Bioeng. 54 (1997) 503-512
23. Oliva A., Santovena A., Farina J., and Llabres M. Effect of high shear rate on stability of proteins: kinetic study. J. Pharm. Biomed. Anal. 33 (2003) 145-155
24. Sluzky V., Klibanov M., and Langer R. Mechanism of insulin aggregation and stabilization in agitated aqueous solutions. Biotechnol. Bioeng. 40 (1992) 895-903
25. Kerwin Jr. B.A., and Remmele R.L. Protect from light: photodegradation and protein biologics. J. Pharm. Sci. 96 (2007) 1468-1479
26. Usami A., Ohtsu A., Takahama S., and Fujii T. The effect of pH, hydrogen peroxide and temperature on the stability of human monoclonal antibody. J. Pharm. Biomed. Anal. 14 (1996) 1133-1140
27. Zheng J.Y., and Janis L.J. Influence of pH, buffer species, and storage temperature on physicochemical stability of a humanized monoclonal antibody LA298. Int. J. Pharm. 308 (2006) 46-51